Dainippon Sumitomo Obtains Caner Drug Rights From Boston Biomedical
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma will pay an upfront $15 million to Boston Biomedical for exclusive rights in Japan to develop and market BB1608, an anticancer agent targeting stem cells